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ABSTRACT 
 
Cervical cancer is second rank cancer in female cancer incidence all over the world and the strategy therapy 
against this disease is addressing cancer cells without endanger normal cells. Discovering potentially selective 
anticancer agent from plants for the treatment of cervical cancer has become a very challenging area of research 
worldwide. Our previous study Anredera cordifolia, commonly named as binahong in Indonesia, revealed cytotoxic 
activity on HeLa cervical cancer cells with IC50 75 µg/mL. However, the selectivity of the chemical agent and its 
molecular target has still remained a question. The current study was aimed at investigating the selectivity of 
ethanolic extract of A. cordifolia leaf (EAC) on Vero cells and its molecular target on HeLa cells. The extracts were 
prepared by macerating Anredera cordifolia leaf powder in 70% ethanol. The assessment of the viability of Vero 
cells was carried out using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; while the 
cell cycle analysis of HeLa cells was probed by using flow cytometry. Based on the cell cycle analysis, the 
molecular target of the extract was investigated by immunocytochemical staining. The present study exhibited the 
selective cytotoxicity of EAC on HeLa cells compared to Vero cells with a Selectivity Index (SI) of 17.36. It 
arrested cell cycle on G1/S phase and suppressed Bcl–2 expression, anti-apoptotic protein, which also regulates 
cell cycle. Therefore, the current piece of work endorses the use of EAC as a promising anticancer agent in the 
treatment of cervical cancer. EAC may be used as a selective anticancer agent on HeLa cells. 
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INTRODUCTION 
 
According to the WHO report (2013, 2014) 
cervical cancer is one of the most prevaling type 
of cancers among women all over the world and 
ranks second in the female cancer incidence in 
ASEAN (Jan et al. 2012). It is one of the major 
causes of deaths among female cancer patient in 
Indonesia, with an addition of 20,928 new 
cervical cancer cases annually (Bruni et al. 2017). 
Its pattern of occurrence gradually shifted from 
developed to developing countries (Torre et al. 
2015). Since the number of cases of cervical 
cancer has alarmingly gone up, several strategies 
have been, therefore, executed for the treatment 
of cervical cancer such as chemotherapy, 
radiation, and their combination (Hong 2006).  
Currently, cisplatin; cis-
[Pt(II)(NH(3))(2)Cl(2)] ([PtCl2(NH3)2] is 
considered one of the most widely used 
chemotherapeutic agents for the treatment of 
cervical cancer (Hu et al. 2012). It has also been 
clinically tested for the other types of cancer, 
such as bladder cancer (Drayton & Catto 2012), 
head and neck cancer (Pendleton & Grandis 
2012), lung cancer (Ahmadzadeh et al. 2015) and 
gastric cancer (Ahmadzadeh et al. 2015; Huang et 
al. 2016). However, there are several reports of 
severe side effects in patient associated with this 
chemical such as nephrotoxicity and bone 
marrow suppression resulting in hematologic 
toxicity as well as increased resistance in cancer 
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cells (Drayton & Catto 2012; Huang et al. 2016; 
Florea & Büsselberg 2011; Hu et al. 2012; 
Prasaja et al. 2015). This setback can be 
attributed to its limited selectivity between 
cancer cells and normal cells. Therefore, 
extensive studies have been conducted so far in 
order to discover and develop a novel selective 
anticancer agent for using in anticancer 
therapies.  
Indonesia has natural products that are 
potentially active against cervical cancer cells 
(Larasati et al. 2014) including Anredera cordifolia 
(Ten) Steenis which is commonly named 
binahong in Indonesia. Its leaves contain a 
compound 8-glucopyranosil 1-4’,5,7 
trihydroxyflavone that has previously been 
demonstrated as an active antioxidant (Jamil 
2012).  Natural antioxidant compounds can 
selectively inhibit tumor cell proliferation and 
have the potential to be explored as 
chemopreventive agent on cervical cancer (Di 
Domenico et al. 2012). In our previous studies, 
A. cordifolia extracts successfully exhibited 
cytotoxic activity as well as apoptosis induction 
in HeLa cells with an IC50 value 75 µg/mL 
without interfering with p53, a tumor suppressor 
protein (Yuliani et al. 2015). However, its 
selectivity of cytotoxic effect towards on  HeLa 
than normal cells has yet to be ascertained.  
The current study was conducted to explore 
the selective cytotoxic effect of ethanolic 
extracts of A. cordifolia leaves (EAC) towards 
Vero cells, as a model system of normal cells, by 
calculating Selectivity Index. Furthermore, the 
molecular pathway of EAC in HeLa cells was 
also determined by cell cycle analysis using flow 
cytometric method and more specifically using 
immunocytochemical staining. 
 
 
MATERIALS AND METHODS 
 
Extract Preparation 
The A. cordifolia leaves were collected from 
the Herbal Garden located in the Faculty of 
Pharmacy, Sanata Dharma University,  
Maguwoharjo, Depok, Yogyakarta. The extracts 
were prepared according to the previous report 
(Yuliani et al. 2015).  First, the leaves were dried 
and extracted using maceration method with 
70% ethanol (Merck Milipore Cat 
No.1.00983.2511). The extract was soaked in 
70% ethanol in erlenmeyer flask for 72 hours 
and repeat it until get clear macerat. The extract 
was collected and concentrated using a rotary 
evaporator (Bucchi, Rotavapor R-300) followed 
by freeze drying in a lyophilizer (VirTis BTK, SP 
Scientific, Gardiner, NY, USA). All these 
processes were carried out in the 
Phytochemistry Laboratory, Sanata Dharma 
University. The extract was stored in tightly 
amber bottles in refrigerator 4°C (Samsung Type 
RT32FARCDSA). For longer use, the extract 
was kept in -20°C.   
 
Materials: Cytotoxicity, Flow cytometry, and 
Immunocytochemical Assay 
The Vero cells and HeLa cervical cancer cells 
used in the current research were procured from 
the Parasitology Laboratory, Faculty of 
Medicine, Universitas Gadjah Mada. The cells 
were cultured and maintained in Roswell Park 
Memorial Institute Medium (RPMI) (Gibco, 
USA Cat.No.11875093) supplemented with Fetal 
Bovine Serum (FBS) 10% (v/v) (Gibco, GI, USA 
Cat. No.16000044) and 1% (v/v) penicillin-
streptomycin (Gibco, USA Cat. No. 15070063). 
Dimethyl sulfoxide (DMSO) (Merck, Germany 
Cat. No. 1.02952.2500) was used to dissolve 
stock solution of extract and cisplatin (Cisplatin 
Kalbe 10 mg/10mL) was used as a positive 
control. The cytotoxic effect was determined 
using 3-[4,5-dimethylthiazol–2-yl]–2,5 diphenyl 
tetrazolium bromide (MTT) (Sigma, Missouri, 
USA Cat. No.M2003-1G) and the formazan 
complex was dissolved in 10% sodium duodecyl 
sulphate (SDS) (Sigma Cat. No. L3771). The 
flowcytometric analysis was carried out using 
propidium iodide kit (BD Bioscience Cat. 
No.556463), 0.1% Triton X solution (Sigma-
Aldrich, Cat. No. T9284), 0.2% RNAse solution 
(Sigma, MO, USA Cat. No. R4642) and 5% 
propidium iodide solution (Sigma-Aldrich, 
Cat.No. P4170) in Phosphate Buffer Saline 
(PBS) (Gibco Cat No.70011044). For 
Immunocytochemical staining, BCl–2 primary 
antibodies were purchased from Novus 
Biologicals (Cat. No. NB100–56098, Littleton 
USA), while secondary antibody was diluted 
from Starr Trek HRP universal detection system 
(Control No. 901-STUHRP700–090314, USA). 
The 96-well plate and 6 well plate used in this 
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study were supplied by Iwaki®, and 
micropipette tips of all sizes were supplied by 
Axygen®. FACS tubes were supplied by BD 
Biosciences, Falcon Cat.No.352054. 
 
MTT Cytotoxicity Assay on Vero Cells 
Cytotoxicity assay on Vero cells was designed 
based on our previous studies (Yuliani et al. 
2015; Setiawati 2016). Vero cells were cultivated 
in a culture flask up to 80% confluency, and 
then 5 × 103 cells in 100 μL medium were 
seeded in a 96-well microplate. The cells were 
cultured in an incubator at 37°C and 5% CO2. 
The medium was discarded and the cells were 
soaked twice using PBS. The initial stock 
solution of EAC and cisplatin were prepared by 
dissolving them into DMSO and later diluted 
with DMEM to obtain different concentrations. 
The medium was replaced with 100 µL medium 
containing EAC and cisplatin concentration into 
each well of the 96-well microplate and analyzed 
three times in each set. The range concentration 
of EAC was 500, 1000, 1500, 2500, 3000 and 
4000 µg/mL while the range of cisplatin 
concentrations were 20, 30, 40, 60, 70 and 80 
µM. The treated cells were incubated at the same 
condition as the previous step. The medium was 
then eliminated and replaced with the medium 
containing 10% MTT in each well. The reaction 
between MTT and succinate hydrogenase of 
cells leads to the formation of formazan crystals 
within 3 to 4 h. After 4 h of incubation, 100 µL 
of 10% SDS solution was added to each well to 
dissolve formazan crystals. The microplates 
were wrapped with aluminum foil to avoid light 
exposure and incubated for 12–24 h, finally the 
formazan complex was determined in 595 nm 
visible wavelength by using ELISA reader (Bio-
Rad). 
 
Flowcytometric Assay 
In order to analyze the cell cycle of HeLa 
cells, the flow cytometric assay was performed  
(Setiawati 2016). The cells were cultured in a 6 
well plate at the density of 1 × 106 cells in 2000 
µL medium per treatment and incubated at 37 
oC under 5% CO2 for 24 h. The extracts were 
prepared at a concentration of 75 µg/mL, 
showing the IC50 towards HeLa cells (Yuliani et 
al 2015). They were poured into the precise flask 
and incubated for 12 and 24 h. The cells were 
separated from the flask by pouring trypsin 
solution and eventually were washed and 
collected by centrifugation at 2000 rpm for 3 
min. Finally, the cell pellets were rinsed with 
phosphate buffer saline (PBS) solution three 
times at 5 °C. The cells were suspended in a 
propidium iodine solution (10 μg/mL) 
containing 300 μg/mL RNase and incubated for 
10 min in a water bath. The cells were 
transferred into a flowcyto vial and analyzed by 
FACSCalibur flow cytometer (Becton, 
Dickinson and Company). 
 
Immunocytochemistry Assay 
The HeLa cells at a density of 105 per 1000 
µL were cultured on a coverslip inside 24-well 
plate and incubated at 5% CO2 and 37 °C for 24 h. 
Subsequently, the cells were rinsed in PBS 
solution three times. The solution of EAC and 
cisplatin at IC50 concentration (Yuliani et al. 
2015) were added to the cells and incubated for 
24 h and rinsed in PBS solution three times.  
Cold methanol was added to the cells on the 
coverslips and incubated for 10 min and then 
methanol was removed and the cells were 
washed three times using PBS solution. The 
coverslips containing cells were transferred to 
the object glass. Hydrogen peroxidase was 
added to the object glass and it was incubated at 
room temperature for 10–15 min. The PBS 
solution was gently dropped onto the coverslips 
to wash the cells. The monoclonal antibody of 
Bcl–2 was added to the coverslips and incubated 
for 1 h at room temperature. The cells were 
rinsed three times with PBS and following this, 
the secondary antibody was also added to the 
coverslips, incubated at room temperature for 
15 min. The traces of secondary antibody were 
removed by pouring PBS solution three times. 
The cells were stained with the chromogen 
solution of 3, 3'-diaminobenzidine (DAB) for 8 
min. Finally, the cells were gently rinsed in 
distilled water and stained with hematoxylin-
eosin for 4 min. The intensity of Bcl–2 
expressions was observed under an inverted 
microscope (Axiovert 40 CFL, Zeiss). 
 
Data Analysis 
The viability of Vero cells was calculated 
from MTT data using the following formula: 
Sample treatment absorbance – Medium absorbance 
X 100% 
Untreated cells absorbance – Medium absorbance 
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The cell viability data were analyzed using 
regressions fit on Microsoft Excel 2013 to 
calculate IC50 of EAC and cisplatin. 
Furthermore, the Selectivity Index (SI) was used 
to calculate and determine the differential 
selectivity of extracts and cisplatin towards 
cancer cells and normal cells. This SI was 
calculated by the ratio of IC50 towards Vero cells 
and IC50 towards HeLa cells (Calderón-arancibia 
et al. 2015). The number of cells, out of 10,000 
HeLa cells in each phase, was determined using 
ModFit LT 3.0TM software using FACS caliber. 
In addition to that, the number of Bcl–2 
expressing cells was qualitatively analyzed. 
 
 
RESULTS AND DISCUSSION 
 
The present study evaluated the selective 
cytotoxic effects of ethanolic extracts of A. 
cordifolia leaves (EAC) towards Vero cells and 
also determined the molecular targets of EAC in 
HeLa cervical cancer cells. Vero cells represent a 
mammalian cell line derived from the kidney of 
the African green monkey (Cercopithecus aethiops) 
and are recommended for in vitro screening the 
chemical toxicity (International Standard ISO 
2009; Menezes et al. 2013). Cisplatin is applied as 
first-line chemotherapy in cervical cancer in 
single or combination with other 
chemotherapeutic agents (Sundar et al. 2003). 
The cytotoxic effect of A. cordifolia extracts and 
cisplatin on Vero cells was measured by MTT 
assay. Figures 1 and 2 revealed the cytotoxic 
effect of EAC and cisplatin on Vero cells. The 
extract showed the cytotoxic effect at a 
concentration applied above 1000 µg/mL and 
its cytotoxic profile followed the polynomial 
order 4 with IC50 value at 1302 µg/mL [Figure 
1]. On the other hand, cisplatin demonstrated 
strong cytotoxic effect with IC50 value at 64 µM 
on Vero cells [Figure 2]. 
 
 
Figure 1  Effect of EAC on Vero cell viability 
 
 
Figure 2  Effect of Cisplatin on Vero cell viability 
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In this study, the calculated Selectivity Index 
(SI) was used to determine selectivity cytotoxic 
effect of EAC and cisplatin. Higher SI value 
refers to a higher selective cytotoxic effect of an 
extract or a compound, a selective extract or 
compound has SI higher than 3 
(Mahavorasirikul et al. 2009). In this study, SI 
was calculated based on IC50 value of extract (75 
µg/mL) and cisplatin (40 µM or equal to 11.9 
µg/mL) on HeLa cells concluded from our 
previous studies (Yuliani et al. 2015; Setiawati 
2016). The data recorded that EAC had a 
significantly higher selectivity to the HeLa cells 
(SI 17.36) than cisplatin (SI 1.60). Therefore, 
EAC has enormous potential to be developed as 
an anticancer agent for the treatment of cervical 
cancer. On the other hand, a lower selectivity is 
shown by cisplatin than EAC may be attributed 
to the formation of active species that interacts 
primarily with DNA via formation of DNA 
crosslinks (Hassan et al. 2014), so that cisplatin 
interferes with DNA both in normal as well as 
cancer cells. However, the investigation of 
selectivity of A. cordifolia extracts endorsed with 
the molecular target in cervical cancer cells is an 
interesting observation. 
 In addition, flow cytometric method was 
employed in this study to assess the cell cycle of  
HeLa cells during EAC treatment. The cells 
were accumulated more in G0/G1 phase due to 
the extract treatment (67.91 ± 6.43 %) [Figure 3] 
compared to the untreated cells (59.72 ± 
3.38%); while in our previous studies cisplatin 
treatment on HeLa cells triggered the cell 
accumulation on G2/M (Setiawati 2016). 
Investigating the molecular target of G0/G1 cell 
cycle arrest was very interesting in this study. 
The regulation of cell cycle is an important 
molecular target in cervical cancer therapy that is 
induced by Human Papilloma Virus (HPV) 
(Fernandes et al. 2003). Cell cycle analysis 
demonstrated that EAC stimulated HeLa cells to 
delay the G0/G1 phase, while our preceding 
studies presented that cisplatin-induced HeLa 
accumulation in the G2/M phase (Setiawati 
2016). Furthermore, the molecular mechanism 
of triggered by the extract was further elucidated 
by immunocytochemical staining method on 
Bcl–2. Bcl–2 protein is significantly over-
expressed in cervical cancer than normal cells 
(Eifler et al. 2014; Zhou & Wang 2015). The 
Bcl–2 protein family plays an important role in 
the regulation of the mitochondrial apoptotic 
pathway, Bcl–2 expressing cells showed brown 
color while non-expressing cells showed purple 
color staining (Figure 4). Untreated HeLa cells 
were stained brown color, while EAC and 
cisplatin treated cells were stained in blue color. 
This result indicated that Bcl–2 expression was 
suppressed by extract and cisplatin.  
 
 
 
 
 
 
 
 
 
 
Figure 3  Cell cycle analysis of HeLa cells; (A) Untreated cells,  (B) EAC 75 µg/mL treated cells 
 
   
A B C 
Figure 4. The expression of Bcl–2 in HeLa cells detected by immunohistochemistry method under a light microscope at 
400X magnification. Brown color (arrow) in cells refers to a positive result. (A) Untreated cells,  (B) EAC 75 
µg/mL treated cells, (C) Cisplatin 40 µM treated cells 
A B 
G0/G1 59.72% ± 3.38 % 
G2/M  13.50% ± 1.10 % 
S          26.78% ± 2.30 % 
G0/G1 67.91 ± 6.43 % 
G2/M    7.19 ± 0.70% 
S          24.50% ± 3.20 
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This study showed that both of EAC and 
cisplatin suppressed the Bcl–2 expression in 
HeLa cells. The down-regulating effect of Bcl–2 
in cisplatin-treated HeLa cells indicated that the 
cells are not resistant to cisplatin (Leisching et al. 
2015). The Bcl–2 protein family contain two 
functional subfamilies of proteins: pro-apoptotic 
proteins (Bax and Bid) and anti-apoptotic 
proteins (Bcl–2 and Bcl-xL). The subfamily of 
Bcl–2 proteins binds to apoptosis protein and 
neutralizes its activity and induces apoptosis 
(Terrano et al. 2010). The downregulation of 
Bcl–2 contributes to the escape of cancer cells 
from death (Koff et al. 2015) and play an 
important role in cell cycle regulation (Naser et al. 
2015). However, anti-apoptotic activity of Bcl–2 
is prevented by Bax activity, a dominant pro-
apoptotic protein of Bcl–2 family (Weinberg 
2007). Bax protein induces cytochrome C to be 
released from mitochondria and cause 
apoptosis. Therefore, a comprehensive 
assessment of both Bcl–2 and Bax protein 
expression gives a clearer molecular mechanism 
of the extract. The ratio of Bax/Bcl–2 
expression indicated the intrinsic pathway of 
apoptosis induction through the release of 
cytochrome C from mitochondrion. This ratio is 
a critical determinant of a cell’s threshold for 
undergoing apoptosis (Zhang et al. 2014). The 
higher value of this ratio indicates a compound 
or an extract with an apoptotic induction activity 
through the intracellular mitochondrial pathway 
(Peng et al. 2015). However, the ratio of 
Bax/Bcl–2 expression was not determined in 
this study. Therefore, efforts will be made in the 
futures studies in order to delineate the 
molecular mechanisms further. 
 
 
CONCLUSION 
 
Anredera cordifolia showed selective cytotoxic 
activity in HeLa cells compared to Vero cells 
through arrested cell cycle at G1/S phase by 
down regulating Bcl–2 expression. Further, a 
clear molecular mechanism of Anredera cordifolia 
should be determined. 
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